Table 2.
Oncologic outcomes
| Total | ALND* | SLNB†+ALND | SLNB Alone | p | |
|---|---|---|---|---|---|
| n = 81 | n = 31 (38%) | n = 25 (31%) | n = 25 (31%) | ||
| BC ‡ Recurrence | 20 (25%) | 11 (36%) | 7 (28%) | 2 (8%) | 0.018 |
| Local Only | 3 (4%) | 2 (7%) | - | 1 (4%) | 0.191 |
| Regional Only | - | - | - | - | - |
| Distant Only | 14 (17%) | 8 (26%) | 6 (24%) | - | 0.023 |
|
Regional + Distant |
2 (2%) | 1 (3%) | - | 1 (4%) | 0.622 |
| Contralateral | 1 (1%) | - | 1 (4%) | - | 0.322 |
| BC Recurrence by Subtype (n = 20) | 0.256 | ||||
| ER+/HER2-§‖ | 7 (35%) | 6 (55%) | 1 (14%) | - | |
| ER+/HER2+ | 6 (30%) | 2 (18%) | 3 (43%) | 1 (50%) | |
| ER-/HER2+ | - | - | - | - | |
| TNBC¶ | 7 (35%) | 3 (27%) | 3 (43%) | 1 (50%) | |
| BC Deaths | 10 (12%) | 4 (13%) | 6 (24%) | - | 0.022 |
| BC Deaths by Subtype (n = 10) | 0.329 | ||||
| ER+/HER2- | 3 (30%) | 2 (50%) | 1 (17%) | - | |
| ER+/HER2+ | 2 (20%) | - | 2 (33%) | - | |
| ER-/HER2+ | - | - | - | - | |
| TNBC | 5 (50%) | 2 (50%) | 3 (50%) | - |
*ALND = axillary lymph node dissection, †SLNB = sentinel lymph node biopsy, ‡BC = breast cancer, §ER = estrogen receptor, ‖HER2 = human epidermal growth factor receptor-2, ¶TNBC = triple negative breast cancer